BriaCell Therapeutics Corp (BCTX)
NASDAQ:BCTX
Want to see BCTX full AI Analyst Report?
BCTX Stock Chart & Stats
$7.28
-$0.02(-3.38%)
At close: 4:00 PM EST
$7.28
-$0.02(-3.38%)
Day’s Range― - ―
52-Week Range$2.98 - $37.20
Previous Close$0.41
Volume996.24K
Average Volume (3M)71.25K
Market Cap
$21.77M
Enterprise Value-$22.49M
Total Cash (Recent Filing)$29.65M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.23
Next Earnings
Jun 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-14.56
Shares Outstanding7,250,487
10 Day Avg. Volume65,395
30 Day Avg. Volume71,255
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.17
Price to Sales (P/S)0.00
P/FCF Ratio-0.15
Enterprise Value/Market Cap-1.03
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit223.31
Enterprise Value/Ebitda0.62
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clean Balance SheetZero total debt and repaired equity materially reduce financial risk for a clinical-stage developer. This durable strength lowers interest and covenant pressure, increases strategic optionality for partnerships or raises, and extends runway versus indebted peers over months.
Focused Immunotherapy PipelineA concentrated focus on immuno-oncology and a clear lead asset (Bria-IMT) creates durable strategic clarity. Specialization in a structural growth area improves expertise, trial design consistency, and partnership appeal, supporting long-term value if clinical milestones progress.
Industry-aligned R&D ProfileOperating losses are consistent with the clinical-stage biotech model, signaling deliberate R&D investment rather than operational failure. This alignment with industry norms permits milestone-driven financing and valuation shifts as trials advance over the next several months.
Bears Say
No Revenue; Widening LossesAbsence of revenue and a ~45.8M TTM net loss undermine internal funding capacity and increase reliance on external capital. Over a 2–6 month horizon this erodes runway and heightens dilution or partnership pressure, constraining strategic flexibility for the company.
High Cash BurnSustained negative operating and free cash flow (~-37M TTM) converts accounting losses into real cash depletion. Rising absolute burn increases the probability of near-term financing, potentially on dilutive or restrictive terms, pressuring execution of multi-month clinical programs.
Weak Shareholder ReturnsDespite repaired equity, very negative ROE and weak returns signal the capital base currently fails to generate profits. This durable weakness can raise cost of capital, reduce investor appetite, and impair ability to leverage equity improvements for favorable financing over months.
BriaCell Therapeutics News
BCTX FAQ
What was BriaCell Therapeutics Corp’s price range in the past 12 months?
BriaCell Therapeutics Corp lowest stock price was $2.98 and its highest was $37.20 in the past 12 months.
What is BriaCell Therapeutics Corp’s market cap?
BriaCell Therapeutics Corp’s market cap is $21.77M.
When is BriaCell Therapeutics Corp’s upcoming earnings report date?
BriaCell Therapeutics Corp’s upcoming earnings report date is Jun 17, 2026 which is in 27 days.
How were BriaCell Therapeutics Corp’s earnings last quarter?
BriaCell Therapeutics Corp released its earnings results on Mar 10, 2026. The company reported -$2.613 earnings per share for the quarter, missing the consensus estimate of N/A by -$2.613.
Is BriaCell Therapeutics Corp overvalued?
According to Wall Street analysts BriaCell Therapeutics Corp’s price is currently Overvalued.
Does BriaCell Therapeutics Corp pay dividends?
BriaCell Therapeutics Corp does not currently pay dividends.
What is BriaCell Therapeutics Corp’s EPS estimate?
BriaCell Therapeutics Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BriaCell Therapeutics Corp have?
BriaCell Therapeutics Corp has 7,250,487 shares outstanding.
What happened to BriaCell Therapeutics Corp’s price movement after its last earnings report?
BriaCell Therapeutics Corp reported an EPS of -$2.613 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 13.911%.
Which hedge fund is a major shareholder of BriaCell Therapeutics Corp?
Currently, no hedge funds are holding shares in BCTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BriaCell Therapeutics Corp
BriaCell Therapeutics Corp., an immuno-oncology-focused biotechnology company, engages in developing immunotherapies for the management of cancer. Its lead drug candidate is Bria-IMT, a whole-cell cancer vaccine that is in Phase I/IIa clinical trials in combination with the immunotherapy development candidates retifanlimab. The company is also developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test that determines the patients' HLA types. It has a non-exclusive clinical trial collaboration with Incyte Corporation to evaluate the effects of combinations of novel clinical candidates; and a cooperative research and development agreement with the National Cancer Institute to conduct preclinical studies to develop and test Bria-OTS cellular immunotherapy as a treatment for cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
Technical Analysis
Rapid Dose Therapeutics Corp
―
Microbix Biosystms
―
Resverlogix
―
Devonian Health Group
―
Thiogenesis Therapeutics Corp
―
Ownership Overview
45.18% Insiders
5.11% Other Institutional Investors
49.70% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---